HC Wainwright Reiterates “Buy” Rating for XOMA (NASDAQ:XOMA)

HC Wainwright restated their buy rating on shares of XOMA (NASDAQ:XOMA) in a report issued on Friday morning,Benzinga reports. They currently have a $123.00 target price on the biotechnology company’s stock.

XOMA Trading Down 3.1 %

NASDAQ XOMA opened at $27.15 on Friday. The company has a market cap of $319.83 million, a PE ratio of -7.80 and a beta of 0.88. The company has a current ratio of 7.52, a quick ratio of 7.52 and a debt-to-equity ratio of 1.28. The stock has a 50 day moving average of $30.05 and a 200-day moving average of $27.71. XOMA has a 12 month low of $15.56 and a 12 month high of $35.00.

Insider Activity at XOMA

In other XOMA news, CEO Owen Hughes sold 21,881 shares of the stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $29.95, for a total value of $655,335.95. Following the transaction, the chief executive officer now directly owns 34,979 shares of the company’s stock, valued at $1,047,621.05. This represents a 38.48 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 7.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On XOMA

Institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC boosted its position in shares of XOMA by 0.6% in the third quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company’s stock valued at $4,840,000 after acquiring an additional 1,138 shares during the period. State Street Corp raised its stake in XOMA by 1.2% in the 3rd quarter. State Street Corp now owns 142,857 shares of the biotechnology company’s stock worth $3,783,000 after purchasing an additional 1,754 shares in the last quarter. Bank of New York Mellon Corp raised its stake in XOMA by 3.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock worth $1,484,000 after purchasing an additional 1,968 shares in the last quarter. Ellsworth Advisors LLC bought a new stake in XOMA in the 3rd quarter valued at about $516,000. Finally, Barclays PLC grew its position in shares of XOMA by 300.7% during the 3rd quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock worth $298,000 after purchasing an additional 8,447 shares in the last quarter. Institutional investors own 95.92% of the company’s stock.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.